Metformin Linked to Lower Mortality in ICU Patients with Diabetes and Heart Failure

A groundbreaking study has been published in the esteemed journal, Cardiovascular Innovations and Applications. This study has brought to light a significant breakthrough for the healthcare industry, as it assesses the mortality rates of patients with diabetes mellitus (DM) and chronic heart failure (CHF) who have been treated with metformin. This further validates why Metformin is a powerful medicine for treating diabetes and heart failure.

Patients receiving intensive care often have diabetes mellitus together with chronic heart failure. Since time immemorial, the use of metformin for these patients has been a controversial subject. In the last decade, metformin has been clinically proven to handle diabetic issues but many healthcare practitioners still uphold that it shouldn’t be used for patients in intensive care units who are battling heart failure and diabetes.

In the study published in the Cardiovascular Innovations and Applications journal the Medical Information Mart for Intensive Care database was used to identify patients with type 2 diabetes mellitus (T2DM) and CHF. A 90-day mortality comparison was conducted between patients who were and were not administered metformin. Propensity score matching analysis and multivariable Cox proportional hazard regression were used to ensure the robustness of theirour results.

A total of 2153 patients (180 receiving metformin and 1973 not receiving metformin) with T2DM and CHF were included in the study. The 90-day mortality rates were 30.5% (601/1971) and 5.5% (10/182) in the non-metformin and metformin groups, respectively. In the propensity score matching analyses, metformin use was associated with a 71% lower 90-day mortality (hazard ratio, 0.29; 95% confidence interval, 0.14-0.59; P < 0.001). The results were insensitive to change when sensitivity analyses were performed.

The results showed that the patients who were taking metformin had a significantly lower mortality rate compared to those who were not taking the medication. Metformin is a medication that is widely used to lower glucose levels and manage blood sugar in patients with type 2 diabetes. Recent studies suggest that Metformin may have additional benefits beyond diabetes control. Some clinicians and scientists have proposed that Metformin could positively impact several hallmarks of aging, extend health span, and even increase longevity.

Metformin works by primarily blocking the production of glucose by the liver, a process known as gluconeogenesis. This helps to gradually bring down blood sugar levels when combined with a healthy diet and exercise. Additionally, studies have shown that Metformin may have anti-inflammatory effects, boost the immune system, and even improve gut microbiome health.

In addition to its metabolic benefits, Metformin has been associated with weight loss, reduced risk of strokes and heart attack, decreased inflammation and stress hormones, lower risk of cancer, age-related diseases, and dementia. It has also been shown to be effective in treating polycystic ovary syndrome (PCOS). These findings suggest that Metformin may have a significant impact on overall health and could be a valuable tool for aging-related diseases.

For more information about Metformin, please visit

About Ageless Rx

AgelessRx is an online telemedicine clinic that specializes in anti-aging. If one isyou are looking for Longevity products to slow down the accumulation of aging-related damage, this online platform can service clients in all 50 states via its website. AgelessRx provides a better alternative to traditional anti-aging clinics. Their ability for patients to get Doctor-assisted care and prescribed products from the comfort of their homes has eliminated the geographical constraints of finding a convenient anti-aging clinic.

Media Contact

Company Name
Contact Name
Anar Isman
2370 E Stadium Blvd #2049
Ann Arbor
Postal Code
United States

comtex tracking